Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CDx: more partnerships ahead, but more pharma awareness needed

This article was originally published in Scrip

Executive Summary

Arguably the most significant catalyst for the greater adoption of personalised medicine came in July 2011 when the US FDA issued its draft guidance on companion diagnostics (scripintelligence.com, 18 July 2011). It didn’t do the whole job, in that it still leaves questions open about how to design and conduct clinical trials. But it did provide a clear signal that the pharma industry should continue moving towards adopting a bigger role for diagnostics as its business model evolves.

You may also be interested in...



Public Health Threat For EU Patients If IVDR Implementation Issues Remain Unaddressed

The IVDR implementation schedule is problematic. European notified bodies say solutions must be grasped if public health is not to suffer.

Compare And Contrast: New UKCA Marking System Will Stress Safety, Quality And Agility

How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.

Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Topics

Related Companies

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel